CareRx Corporation

TSX:CRRX.TO

Medical - Care Facilities

Healthcare
$3.21 +0.63%

+$0.02 today

Market cap
$203.06M
Beta
0.62
P/E (TTM)
7.4
EPS (TTM)
$0.43
Dividend yield
1.88%
52W Low $2.70High $4.00

Volume 0.01M

Average 0.04M

CRRX.TO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

CareRx CorporationTSX: CRRX.TO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of CA$454K rose 7.6% year over year, ahead of the -37.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 64.1% from the prior quarter. Over 3 fiscal years it compounded at -15.9% a year.

Context

  • Stock-based compensation amounted to 0.7% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +7.6% holds above the trailing-twelve-month pace of -37.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$454K-64.1% QoQ
Last fiscal yearDec 2025
CA$2.72M-25.7% YoY
LTMMar 2026
CA$2.25M-37.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.6%——
1 year-25.7%——
3-year CAGR-15.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

CAD · from the cash flow

Latest · FY2025
2.72M CAD
Year-over-year change
-25.7%
4-year CAGR
+0.5%

Stock-Based Compensation vs competitors

How CRRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -37.4% is the 5th highest of 6, against a peer median of +5.0%.
  • Stock-based compensation amounts to 0.6% of revenue for CRRX.TO, versus a peer median of 2.8%.
CRRX.TO Competitors
Stock-Based Compensation for CRRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRN.TOProfound Medical Corp.LTM Mar 2026$5.55M USD+98.0%+9.0%29.6%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$4.81M CAD+5.0%+9.4%3.0%
CRRX.TOCareRx CorporationLTM Mar 2026CA$2.25M CAD-37.4%-15.9%0.6%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$1.4M USD-30.3%-13.2%2.5%
DR.TOMedical Facilities CorporationLTM Mar 2026$246K USD+228.0%—0.1%
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$0 CAD-100.0%——
Peer median (excluding CRRX.TO) —+5.0%+9.0%2.8%

Competitors are the stored peer set for CRRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(22.73M)(34.35M)(5.41M)(4.5M)26.13M
Depreciation & Amortization15.39M20.07M19.98M19.19M18.33M
Deferred Income Tax(1.01M)(1.54M)(4.19M)32K(22.77M)
Stock-Based Compensation2.67M4.57M1.47M3.65M2.72M
Change in Working Capital(3.73M)638K2.12M8.98M(988K)
Accounts Receivables(11.72M)1.51M1.47M3.82M247K
Inventory(2.83M)(2M)648K1.55M(126K)
Accounts Payables15M816K(181K)3.46M(891K)
Other Working Capital(4.17M)307K186K145K(218K)
Other Non-Cash Items16.67M32.96M13.4M10.64M4.12M
Operating Cash Flow7.27M22.33M27.38M37.99M27.54M
Capital Expenditures(7.12M)(13.61M)(8.7M)(8.11M)(5.59M)
Acquisitions (Net)(86.13M)(2.99M)(3.66M)196K39K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities67K(3.57M)(3.93M)(2.53M)0
Investing Cash Flow(93.18M)(16.6M)(12.31M)(7.92M)(8.26M)
Debt Repayment30.35M(5.29M)(39.82M)(21.58M)(4.32M)
Common Stock Issued80.86M1.01M14.68M014K
Common Stock Repurchased00(56K)(801K)(2.24M)
Dividends Paid0000(1.26M)
Other Financing Activities(9.3M)(8.71M)(11.2M)(5.64M)(6.64M)
Financing Cash Flow101.91M(12.99M)(36.4M)(28.02M)(14.44M)
Effect of Forex Changes00000
Net Change in Cash16M(7.25M)(21.34M)2.06M4.84M
Free Cash Flow153K8.72M18.68M29.88M21.95M

CareRx Corporation

TSX:CRRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.